Evidence map›Paper›PMID 38982890›Full record

Observational studyJournal of the International AIDS Society2024

Programme science in action: lessons from an observational study of HIV prevention programming for key populations in Lusaka, Zambia.

Izukanji Sikazwe, Maurice Musheke, Kanema Chiyenu, Benard Ngosa, Jake M Pry, Chama Mulubwa, Martin Zimba, Martin Sakala, Mphatso Sakala, Paul Somwe and 4 more

Abstract readObservational Study
In one paragraph

Observational study in Journal of the International AIDS Society, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Izukanji SikazweCentre for Infectious Disease Research in Zambia (CIDRZ), Lusaka, Zambia.
Maurice MushekeCentre for Infectious Disease Research in Zambia (CIDRZ), Lusaka, Zambia.
Kanema ChiyenuCentre for Infectious Disease Research in Zambia (CIDRZ), Lusaka, Zambia.
Benard NgosaCentre for Infectious Disease Research in Zambia (CIDRZ), Lusaka, Zambia.
Jake M PryCentre for Infectious Disease Research in Zambia (CIDRZ), Lusaka, Zambia.ORCID https://orcid.org/0000-0001-6312-4420
Chama MulubwaCentre for Infectious Disease Research in Zambia (CIDRZ), Lusaka, Zambia.
Martin ZimbaZambia Sex Workers Alliance, Lusaka, Zambia.
Martin SakalaTithandizeni Umoyo Network, Lusaka, Zambia.
Mphatso SakalaIntersex Society of Zambia, Lusaka, Zambia.
Paul SomweCentre for Infectious Disease Research in Zambia (CIDRZ), Lusaka, Zambia.
Goodwin NyirendaCentre for Infectious Disease Research in Zambia (CIDRZ), Lusaka, Zambia.
Theodora SavoryCentre for Infectious Disease Research in Zambia (CIDRZ), Lusaka, Zambia.
Carolyn Bolton-MooreCentre for Infectious Disease Research in Zambia (CIDRZ), Lusaka, Zambia.ORCID https://orcid.org/0000-0001-9103-7746
Michael E HerceCentre for Infectious Disease Research in Zambia (CIDRZ), Lusaka, Zambia.ORCID https://orcid.org/0000-0002-3629-3867

Funding

CDC HHS NU2GGH001920
6 · The paper itself

Abstract

introductionOptimizing uptake of pre-exposure prophylaxis (PrEP) for individuals at risk of HIV acquisition has been challenging despite clear scientific evidence and normative guidelines, particularly for key populations (KPs) such as men who have sex with men (MSM), female sex workers (FSWs), transgender (TG) people and persons who inject drugs (PWID). Applying an iterative Programme Science cycle, building on the effective programme coverage framework, we describe the approach used by the Centre for Infectious Disease Research in Zambia (CIDRZ) to scale up PrEP delivery and address inequities in PrEP access for KP in Lusaka, Zambia.

methodsIn 2019, CIDRZ partnered with 10 local KP civil society organizations (CSOs) and the Ministry of Health (MOH) to offer HIV services within KP-designated community safe spaces. KP CSO partners led KP mobilization, managed safe spaces and delivered peer support; MOH organized clinicians and clinical commodities; and CIDRZ provided technical oversight. In December 2021, we introduced a community-based intervention focused on PrEP delivery in venues where KP socialize. We collected routine programme data from September 2019 to June 2023 using programme-specific tools and the national electronic health record. We estimated the before-after effects of our intervention on PrEP uptake, continuation and equity for KP using descriptive statistics and interrupted time series regression, and used mixed-effects regression to estimate marginal probabilities of PrEP continuity.

resultsMost (25,658) of the 38,307 (67.0%) Key Population Investment Fund beneficiaries were reached with HIV prevention services at community-based venues. In total, 23,527 (61.4%) received HIV testing services, with 15,508 (65.9%) testing HIV negative and found PrEP eligible, and 15,241 (98.3%) initiating PrEP. Across all programme quarters and KP types, PrEP uptake was >90%. After introducing venue-based PrEP delivery, PrEP uptake (98.7% after vs. 96.5% before, p < 0.001) and the number of initiations (p = 0.014) increased significantly. The proportion of KP with ≥1 PrEP continuation visit within 6 months of initiation was unchanged post-intervention (46.7%, 95% confidence interval [CI]: 45.7%, 47.6%) versus pre-intervention (47.2%, 95% CI: 45.4%, 49.1%).

conclusionsApplying Programme Science principles, we demonstrate how decentralizing HIV prevention services to KP venues and safe spaces in partnership with KP CSOs enabled successful community-based PrEP delivery beyond the reach of traditional facility-based services.

Indexed as

HIV InfectionsPre-Exposure ProphylaxisAdultAnti-HIV AgentsFemaleHumansMaleSex WorkersYoung AdultZambiaAnti-HIV AgentsHIV preventionkey populationspre‐exposure prophylaxisPrEPprogramme scienceZambia

Identifiers

PMID38982890
PMCPMC11233926

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.